Aktuelle Neurologie, Inhaltsverzeichnis Aktuelle Neurologie 2018; 45(07): 559-560DOI: 10.1055/a-0646-0803 Kompetenznetz Multiple Sklerose © Georg Thieme Verlag KG Stuttgart · New YorkAktuelles aus der Forschung Authors Institutsangaben L. H. Klotz 1 Klinik für Allgemeine Neurologie, Department für Neurologie, Universitätsklinikum Münster I. Metz 2 Institut für Neuropathologie, Universitätsmedizin Göttingen, Georg-August-Universität Göttingen Artikel empfehlen Abstract Volltext Referenzen Literatur 1 Kappos L, Bar-Or A, Cree BAC. et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet 2018; 391: 1263-1273 2 Weber MS, Derfuss T, Metz I. et al. Defining distinct features of anti-MOG antibody associated central nervous system demyelination. Therapeutic advances in neurological disorders 2018; 11: 1756286418762083 3 Spadaro M, Winklmeier S, Beltran E. et al. Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein. Ann Neurol 2018; [Epub ahead of print] 4 Pearce EL, Pearce EJ. Metabolic pathways in immune cell activation and quiescence. Immunity 2013; 38: 633-43 5 Gerriets VA, Kishton RJ, Nichols AG. et al. Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation. J Clin Invest 2015; 125: 194-207 6 Chang CH, Curtis JD, Maggi Jr LB. et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell 2013; 153: 1239-1251 7 Kornberg MD, Bhargava P, Kim PM. et al. Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity. Science 2018; 360: 449-453
